Gentiva Health Services (NASDAQ: GTIV) said the Company anticipates results from continuing operations for the second quarter ended June 30, 2014, to be equal to or in excess of the following: net revenues of $496 million, adjusted EBITDA of $52 million, and adjusted income attributable to Gentiva stockholders on a diluted basis of $0.33 per share. The Company also furnished an investor presentation to the Securities and Exchange Commission (“SEC”) outlining the reasons that its Board of Directors (the “Board”) has recommended stockholders reject Kindred Healthcare, Inc.’s (“Kindred”) unsolicited and grossly inadequate offer. Gentiva Health Services, Inc. (NASDAQ:GTIV) net profit margin is -21.80% and weekly performance is 0.58%. On last trading day company shares ended up $15.60. Analysts mean target price for the company is $13.75. Gentiva Health Services, Inc. (NASDAQ:GTIV) distance from 50-day simple moving average is 22.24%.
On June 24,2014 Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced the closing of its follow-on public offering of 4,600,000 shares of common stock at a public offering price of $30.50 per share. This includes the exercise in full by the underwriters of their option to purchase up to 600,000 additional shares of common stock at the same price. The net proceeds from the sale of the shares, after deducting the underwriters’ discounts and other estimated offering expense payable by Revance Therapeutics will be approximately $131.3 million. Revance Therapeutics Inc (NASDAQ:RVNC) shares advanced 1.06% in last trading session and ended the day on $31.34. RVNC its return on assets is -45.90%. Revance Therapeutics Inc (NASDAQ:RVNC) quarterly performance is 8.33%.
Ultragenyx Pharmaceutical (NASDAQ: RARE) announced that it has commenced an underwritten public offering of 2,017,349 shares of its common stock. The offering is expected to consist of 1,311,277 shares to be offered by Ultragenyx and 706,072 shares to be offered by selling stockholders. In addition, the company and the selling stockholders are expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an aggregate of an additional 302,602 shares of common stock at the public offering price, less the underwriting discount. Ultragenyx will not receive any proceeds from the sale of any shares sold by the selling stockholders. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) shares moved down -3.38% in last trading session and was closed at $40.00, while trading in range of $37.77-$40.99. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) year to date performance is -5.33%.
Research analysts at Canaccord Genuity initiated coverage on shares of Aerie Pharmaceuticals (NASDAQ:AERI) in a report released on Thursday. The firm set a “buy” rating on the stock. Aerie Pharmaceuticals Inc (NASDAQ:AERI) ended the last trading day at $26.40. Company weekly volatility is calculated as 6.62% and price to cash ratio as 9.51. Aerie Pharmaceuticals Inc (NASDAQ:AERI) showed a positive weekly performance of 5.35%.
On June 16,2014 Acasti Pharma Inc (NASDAQ:ACST) announced Monday that Xavier Harland resigned as the company’s Chief Financial Officer, effective immediately. Acasti Pharma Inc (NASDAQ:ACST) weekly performance is 5.88%. On last trading day company shares ended up $1.08. Analysts mean target price for the company is $6.25. Acasti Pharma Inc (NASDAQ:ACST) distance from 50-day simple moving average is -52.54%.